company background image
APS

Aptose Biosciences TSX:APS Stock Report

Last Price

CA$1.11

Market Cap

CA$102.4m

7D

6.7%

1Y

-65.1%

Updated

16 Aug, 2022

Data

Company Financials +
APS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

APS Stock Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.

Aptose Biosciences Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aptose Biosciences
Historical stock prices
Current Share PriceCA$1.11
52 Week HighCA$3.91
52 Week LowCA$0.90
Beta1.41
1 Month Change2.78%
3 Month Change-17.16%
1 Year Change-65.09%
3 Year Change-63.49%
5 Year Change-39.34%
Change since IPO-99.91%

Recent News & Updates

Aug 05
We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

APSCA BiotechsCA Market
7D6.7%-3.5%2.5%
1Y-65.1%13.7%1.0%

Return vs Industry: APS underperformed the Canadian Biotechs industry which returned 13.7% over the past year.

Return vs Market: APS underperformed the Canadian Market which returned 1% over the past year.

Price Volatility

Is APS's price volatile compared to industry and market?
APS volatility
APS Average Weekly Movement9.4%
Biotechs Industry Average Movement13.0%
Market Average Movement10.6%
10% most volatile stocks in CA Market18.9%
10% least volatile stocks in CA Market4.3%

Stable Share Price: APS is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: APS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198642William Ricehttps://www.aptose.com

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin’s lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.

Aptose Biosciences Inc. Fundamentals Summary

How do Aptose Biosciences's earnings and revenue compare to its market cap?
APS fundamental statistics
Market CapCA$102.44m
Earnings (TTM)-CA$74.30m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
APS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$57.70m
Earnings-US$57.70m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.63
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did APS perform over the long term?

See historical performance and comparison